First-line Treatment of untreated, non-resectable or metastatic   Urothelial Carcinoma: An open, randomized, Phase III Study of Nivolumab   in Combination with Ipilimumab or Standard Chemotherapy versus   Standard-Chemotherapy in Patients with previously untreated inoperable   or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO

Title:: First-line Treatment of untreated, non-resectable or metastatic Urothelial Carcinoma: An open, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or Standard Chemotherapy versus Standard-Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO
Document type:: Editorial Material
Author(s):: Rexer, H.; Retz, M.; Waller, C.
Journal title abbreviation:: Aktuelle Urol
Year:: 2019
Journal volume:: 50
Journal issue:: 1
Pages contribution:: 20-21
Fulltext / DOI:: doi:10.1055/a-0790-9608
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/30731500
Print-ISSN:: 0001-7868
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: